Zero Candida Announces its Intent to Complete Listing of its Shares on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 million Canadian Dollars

TEL AVIV, IsraelJune 3, 2024 /CNW/ — Zero Candida (the “Company” or “ZC “) an Israeli FemTech medical device start-up is pleased to announce that it is in the process of applying to the TSX Venture Exchange in Canada to list its shares at a proposed valuation of 40 million Canadian dollars.

Are you an angel?

Public Announcements

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ — Zero Candida Technologies,…

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…

Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…